Successful treatment of bullous pemphigoid with pulsed intravenous cyclophosphamide. 1996

T Itoh, and H Hosokawa, and Y Shirai, and T Horio
Department of Dermatology, Kansai Medical University, Osaka, Japan.

Pulsed therapy with intravenous cyclophosphamide was successful in a patient with bullous pemphigoid whose disease had proved resistant to other treatments.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D008297 Male Males
D010391 Pemphigoid, Bullous A chronic and relatively benign subepidermal blistering disease usually of the elderly and without histopathologic acantholysis. Pemphigoid,Bullous Pemphigoid,Pemphigoids
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

T Itoh, and H Hosokawa, and Y Shirai, and T Horio
November 1997, The British journal of dermatology,
T Itoh, and H Hosokawa, and Y Shirai, and T Horio
November 2012, Archives of dermatology,
T Itoh, and H Hosokawa, and Y Shirai, and T Horio
January 2001, Archives of dermatology,
T Itoh, and H Hosokawa, and Y Shirai, and T Horio
March 2023, International journal of dermatology,
T Itoh, and H Hosokawa, and Y Shirai, and T Horio
May 2014, Cutis,
T Itoh, and H Hosokawa, and Y Shirai, and T Horio
November 1972, Archives of dermatology,
T Itoh, and H Hosokawa, and Y Shirai, and T Horio
January 2008, Pediatric dermatology,
T Itoh, and H Hosokawa, and Y Shirai, and T Horio
December 1985, Annals of internal medicine,
T Itoh, and H Hosokawa, and Y Shirai, and T Horio
October 2022, Cureus,
Copied contents to your clipboard!